Pro-oxidative activities and dose-response relationship of ()-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro
doi: 10.1002/jnr.22338 141
However, in this case, the patients usually do not show symptoms of metabolic acidosis or hemolytic anemia, and antioxidant therapies are ineffective ( Table 2 Clinical features and laboratory data corresponding to patients diagnosed with GSSD in China
Avoid lying on the affected side if possible
For the MEK inhibitor binimetinib combinations with gemcitabine, cladribine, fluvastatin, and lovastatin, yielded mostly additive effects on cell viability of the four tested NRAS or BRAF-mutated cell lines (Supplementary Table 6)
61 Exendin-(9-39) cannot activate the GLP-1R because this peptide lacks N-terminal residues that engage the TMD core